Trial results for a patient navigator intervention aimed at individuals with Diabetic Retinopathy were posted on ClinicalTrials.gov on 2026-03-11. The pilot study reported that 71 percentage of participants completed a follow-up eye exam 12-18 months after their baseline exam.

Background

Diabetic Retinopathy is a serious complication of diabetes that can lead to vision loss and diabetic blindness. Regular eye examinations are vital for early detection and management. However, patient adherence to recommended screening and follow-up schedules can be challenging. Patient navigator interventions aim to improve patient engagement and ensure timely access to eye care, especially for those at high risk. This pilot study assessed the feasibility and acceptability of such an intervention.

Trial design

This completed pilot study, designated as Phase NA, enrolled 35 participants. The study focused on individuals with Diabetic Retinopathy and those at high risk of Diabetic Blindness. The intervention involved a patient navigator to support participants. The primary objective was to assess the feasibility and acceptability of this intervention in preparation for a larger clinical trial.

Key results

The trial reported key measurements related to participant engagement with eye care:

What this means

The results of this pilot study suggest that a patient navigator intervention is feasible and acceptable for individuals with Diabetic Retinopathy. The high rate of baseline eye exams and the notable percentage of participants completing follow-up eye exams indicate that such an intervention may effectively improve adherence to critical eye care. These findings provide foundational data to support a larger clinical trial to further evaluate the efficacy of patient navigator programs in preventing diabetic blindness.

Source

The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05188703, titled "Patient Navigator Intervention for Diabetic Retinopathy", were posted on 2026-03-11 on clinicaltrials.gov.